Future developments in renal cell carcinoma

Annals of Oncology

Volumn 20, Issue SUPPL.1, 2009, Pages

  Bellmunt, J ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Clinical trials; Metastatic renal cell carcinoma; Sunitinib malate; Targeted agents; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CLINICAL TRIAL; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; KIDNEY NEOPLASMS; TREATMENT OUTCOME;

EID: 66549113411     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp074     Document Type: Article

References (28)

1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
2. Ries LAG, Melbert D, Krapcho M et al. SEER Cancer Statistics Review 1975-2004 http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007. http://seercancergov/csr/1975_2004/2007.
3. Coppin C, Porzsolt F, Awa A et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005 CD001425.
4. Ljungberg B, Hanbury D, Kuczyk M. Guidelines on Renal Cell Carcinoma. Update March 2007 http://www.uroweborg/fileadmin/user_upload/Guidelines/08_Renal_Cell_Carc inoma_2007pdf2007.
5. Pfizer Inc. SUTENT® (sunitinib): Summary of Product Characteristics January 2008.
6. Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008; 2 (May 20 Suppl): Abstr 5024; Oral presentation.
7. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
8. Sternberg CN. Expanding the boundaries of clinical practice: building on experience with targeted therapies. Ann Oncol 2009; 20 (Suppl 1): i1-16.
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer v.1.2008. National Comprehensive Cancer Network http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf (accessed 3 August 2008).
10. Dutcher JP, Wild D, Hudes GR et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J Clin Oncol 2008; 26 (May 20 Suppl): Abstr 5127; Poster presentation.
11. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
12. Shepard DR, Rini BI, Garcia JA et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008; 26 (May 20 Suppl): Abstr 5123; Poster presentation.
13. Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3743-3748.
14. www.clinicaltrials.gov. 2008.
15. Sablin M, Bouaita L, Balleyguier C et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol 2007 June 20 Suppl): Abstr 5038.
16. Tamaskar I, Garcia JA, Elson P et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008; 179: 81-86.
17. Escudier B, Ravaud A, Oudard S et al. Phase-3 randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma. Ann Oncol 2008; 19 (Suppl 8): Abstr 72O; Oral presentation.
18. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
19. Michaelson MD, Schwarzberg A, Ryan D et al. A phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumors. San Francisco, CA, USA: Poster presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium February 14-16, 2008 (Abstr 362).
20. Sosman JA, Flaherty KT, Atkins MB et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 2008; 26 (May 20 Suppl): Abstr 5011; Poster presentation.
21. Azad NS, Posadas EM, Kwitkowski VE et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26: 3709-3714.
22. Whorf RC, Hainsworth JD, Spigel DR et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 2008; 26 (May 20 Suppl): Abstr 5010; Poster presentation.
23. Cooney MM, Garcia JA, Elson P et al. Sunitinib and bevacizumab in advanced solid tumors: A phase I trial. J Clin Oncol 2008; 26 (May 20 Suppl): Abstr 3530; Poster presentation.
24. Feldman DR, Ginsberg MS, Baum M et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26 (May 20 Suppl): Abstr 5100; Poster presentation.
25. Lam JS, Belldegrun AS, Figlin RA. Adjuvant treatment for renal cell carcinoma. Expert Opin Pharmacother 2006; 7: 705-720.
26. Patard JJ, Thuret R, Raffi A et al. Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. Eur Urol 2008 Sept 18 [Published ahead of print].
27. Karakiewicz PI, Suardi N, Jeldres C et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008; 53: 845-848.
28. Pfizer Inc. Data on file.